Explore
Search ClinicalTrials.gov
Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.
Results for “AstraZeneca”
Sponsor: ETOP IBCSG Partners Foundation
Non Small Cell Lung Cancer
Australia, Austria, Belgium, Estonia, France +5 more
- Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLCActive Not Recruiting
Sponsor: AstraZeneca
Lung Cancer
China
- CLL Therapy Approaches in RussiaActive Not Recruiting
Sponsor: AstraZeneca
Chronic Lymphocytic Leukemia
Russia
Sponsor: AstraZeneca
Metastatic Non-small Cell Lung Cancer
United States, Australia, Belgium, Brazil, Canada +22 more
Sponsor: AstraZeneca
Gastric Cancer
United States, China, Japan, South Korea, Spain +2 more
Sponsor: AstraZeneca
Eosinophilic Asthma
United States, Bulgaria, Canada, China, France +8 more
- Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCCActive Not Recruiting
Sponsor: AstraZeneca
Esophageal Squamous Cell Carcinoma
United States, Belgium, Brazil, Canada, China +11 more
Sponsor: Ottawa Heart Institute Research Corporation
Heart Failure
Canada
Sponsor: AstraZeneca
Lung Neoplasms
Brazil
- Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular CarcinomaActive Not Recruiting
Sponsor: AstraZeneca
Hepatocellular Carcinoma
China, Hong Kong
- Real-world Study Assessing Efficacy of TezepeLumaB in Patients With Severe Asthma Regardless of Phenotype in RussiaActive Not Recruiting
Sponsor: AstraZeneca
Severe Asthma
Russia
- A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate CancerRecruiting
Sponsor: AstraZeneca
Metastatic Castration-Resistant Prostate Cancer
United States, Australia, South Africa
Sponsor: AstraZeneca
Chronic Kidney Disease
Indonesia, Vietnam
- Olaparib in Men With High-Risk Biochemically-Recurrent Prostate Cancer Following Radical Prostatectomy, With Integrated Biomarker AnalysisActive Not Recruiting
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate
United States
- A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLCActive Not Recruiting
Sponsor: AstraZeneca
Metastatic Non-Small Cell Lung Cancer (NSCLC)
United States, Austria, Belgium, Poland, Russia +4 more
- A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing TumorsActive Not Recruiting
Sponsor: AstraZeneca
Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
China
- Organ-Preserving Endoscopic Resection & Adjuvant RADIO-immuno-chemotherapy for Esophageal CancerActive Not Recruiting
Sponsor: University of Manitoba
Esophageal Cancer
Canada
Sponsor: AstraZeneca
Hepatic Impairment
United States
- Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation TherapyActive Not Recruiting
Sponsor: Memorial Sloan Kettering Cancer Center
NSCLC · Non-small Cell Lung Cancer · Lung Cancer · Non-small Cell Lung Cancer Stage I
United States
- Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder CancerActive Not Recruiting
Sponsor: Jonsson Comprehensive Cancer Center
Bladder Urothelial Carcinoma · Stage IV Bladder Cancer AJCC v8 · Stage IVA Bladder Cancer AJCC v8 · Stage IVB Bladder Cancer AJCC v8
United States
- AZD6738 for Patients With Progressive MDS or CMMLActive Not Recruiting
Sponsor: Massachusetts General Hospital
Leukemia · Myelodysplastic Syndrome
United States
- A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With DyslipidaemiaActive Not Recruiting
Sponsor: AstraZeneca
Dyslipidaemia
China, Hong Kong
Sponsor: Mehmet Akce
Intrahepatic Cholangiocarcinoma · FGFR2 Gene Rearrangement · FGFR2 Gene Mutation
United States
- Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLCActive Not Recruiting
Sponsor: You Lu
Lung Cancer · Extensive-stage Small-cell Lung Cancer · Durvalumab
China
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Biliary Tract Cancers
United States